[Chronobiology and medicine: from theory to clinical reality].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Corominas Vilardell.
Explore the source record for details and available documents.
A multicentric, double-blind and randomized clinical study was conducted on a total of 54 patients with hyperlipidemias type IIa, IIb and IV in order to compare the effectivity and tolerance of two hyperlipemiant drugs: Binifibrate and Gemfibrozil. The treatment had a length of six months, performing clinical and analytical controls at: baseline, 1 month, 2 months, 4 months and 6 months. Both drugs showed a very good tolerance and the following results were obtained: Total cholesterol: Binifibrate -21.9%, Gemfibrozil -20.5%; Triglycerides: Binifibrate -48.6%, Gemfibrozil -43.27%; HDL: Binifibrate +18.2%, Gemfibrozil -12.8%; LDL: Binifibrate -24.3%, Gemfibrozil -22.8% VLDL: Binifibrate -48%, Gemfibrozil -43.2%; Apo A: Binifibrate +133.5%, Gemfibrozil +108.1%; Apo B: Binifibrate -59.7%, Gemfibrozil -46%. Both treatment were very effective, although the greater increase produced by Binifibrate on Chol-HDL, with a statistically significant difference versus the increase produced by Gemfibrozil, must be highlighted.
Twenty one specimens of cutaneous xanthomas from different types of hyperlipoproteinaemic and normolipidemic xanthomatosis were obtained and analyzed by thin layer chromatography. After separation and development, the areas were determinated by densitometry, and the results are given in percentages for each development. Acording to the results, the following data are of interest: -- Recents xanthomas have greater amount of lipids. -- Cholesterol esters (EC) are prevalent in xanthomas and in normal skin the triglycerides fraction. -- Monoenoic esters (EM) are prevalent on EC chromatography, like in normal skin. -- Finally, there are not significant variations between lipid composition of xanthomas in the different Xanthomatosis.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.